



News release, September 30th, 2020

ASKA Pharmaceutical Co., Ltd.
KYORIN Holdings, Inc.

**Notice regarding the Joint Development and Commercialization Agreement for
[AKP-009], a treatment agent for Benign Prostatic Hyperplasia**

ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") and KYORIN Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, President: Shigeru Ogihara, hereinafter "KYORIN"), a subsidiary of KYORIN Holdings, Inc. (Head Office: Chiyoda-ku, Tokyo, President: Yutaka Ogihara), announced that the two companies of ASKA and KYORIN have entered into a joint development and commercialization agreement regarding [AKP-009, generic name: not yet determined], a treatment agent for Benign Prostatic Hyperplasia developed by ASKA in-house Research and Development.

Under this agreement, ASKA will grant KYORIN the joint development and commercialization rights for [AKP-009] within Japan, and KYORIN will pay ASKA an upfront payment.

The development will be jointly carried out by both companies and the associated cost will be shared. In addition, ASKA is eligible to receive development milestone payments from KYORIN.

[AKP-009], for which ASKA is currently conducting Phase II clinical trial in Japan, has a novel androgen receptor modulator mode of action, and has the potential to exhibit prostatic shrinkage as well as improve urinary function as a novel therapeutic agent for Benign Prostatic Hyperplasia.

ASKA has set "urology" as one of its priority therapeutic areas, and is working to expand its product portfolio as well as enhance its presence within this area. With this agreement, ASKA expects to maximize the value as well as enhance the efficiency of the development for [AKP-009].

KYORIN is promoting a franchise customer strategy that concentrates its management resources on specific therapeutic areas, and with this agreement, will aim to expand its own product portfolio within the therapeutic area of urology which is a priority therapeutic area for KYORIN, and will also aim to further enhance its presence.

ASKA and KYORIN will continue to utilize the strengths and know-how of both companies to obtain an early approval for [AKP-009] in order to further contribute to improving the QOL of patients who are suffering from various Benign Prostatic Hyperplasia symptoms.

Inquiries regarding this matter	
ASKA Pharmaceutical Co., Ltd. Corporate Planning Department TEL: +81-3-5484-8366	KYORIN Holdings, Inc. Corporate Planning TEL: +81-3-3525-4707